US FDA commissioner nominee Stephen Hahn does not offer much detail on his policy positions; Senate confirmation could be completed by the end of the year.
US Food and Drug Administration Commissioner nominee Stephen Hahn kept his answers to Senators questions vague, sometimes irritatingly so, during his Senate confirmation hearing, and emerged largely unscathed from the 20 November event.
Hahn endured nearly two hours of questions from the Health, Education, Labor and Pensions Committee and pledged to work with...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
